125545 Online

For full prescribing information and format items, clinicians can reference the FDA Center for Drug Evaluation and Research records.

: A community discussion on Pilots of America regarding the FAA Handbook and cloud base calculations. 125545Orig1s000 - accessdata.fda.gov 125545

Biologics License Application (BLA) marks a significant milestone in expanding access to anemia treatments. As a biosimilar to US-licensed Epogen, Retacrit (epoetin alfa-epbx) provides a cost-effective alternative for treating anemia caused by chronic kidney disease, chemotherapy, or zidovudine in HIV-infected patients. Key highlights from the FDA review: 125545